As the acquired immunodeficiency syndrome (AIDS) epidemic among drug users enters its third decade in the United States, it is important to consider the role playing by substance abuse treatment in the prevention of human immunodeficiency virus (HIV) infection.|The authors review the research literature, examining findings from studies with behavioral and serologic measures on the association among treatment participation, HIV risk reduction, and HIV infection.|Numerous studies have now documented that significantly lower rates of drug use and related risk behaviors are practiced by injecting drug users (IDUs) who are in treatment. Importantly, these behavioral differences, based primarily on self-report, are consistent with studies that ha...
IntroductionPersons who inject drugs (PWID) continue to be disproportionately affected by HIV. HIV t...
During the last three decades, both the injection of illicit psychoactive drugs and HIV infection am...
Heterosexual contact with intravenous drug users accounts for a growing proportion of cases of acqui...
Over the past decade, a body of observational research has accrued about the effects of outreach-bas...
Since first recognition of the scope of the acquired immunodeficiency syndrome epidemic among the dr...
This exploratory study assesses the utility of substance abuse treatment as a strategy for preventin...
Intravenous drug users are the second most common risk group for acquired immunodeficiency syndrome ...
AbstractEvidence-based strategies to guide human immunodeficiency virus (HIV) prevention for people ...
Major research findings show gaps in health services research on the prevalence and outcomes of pati...
During 2016, 6% of persons in the United States who received a diagnosis of human immunodeficiency v...
Human Immunodeficiency Virus-1 infection is prevalent among injection drug users nationwide, and is ...
Drug abuse is associated with poorer virologic and clinical outcomes for patients with human immunod...
During 2016, 6% of persons in the United States who received a diagnosis of human immunodeficiency v...
Background: Despite the development of antiretroviral therapy (ART), injection drug users (IDU) cont...
IntroductionPersons who inject drugs (PWID) continue to be disproportionately affected by HIV. HIV t...
During the last three decades, both the injection of illicit psychoactive drugs and HIV infection am...
Heterosexual contact with intravenous drug users accounts for a growing proportion of cases of acqui...
Over the past decade, a body of observational research has accrued about the effects of outreach-bas...
Since first recognition of the scope of the acquired immunodeficiency syndrome epidemic among the dr...
This exploratory study assesses the utility of substance abuse treatment as a strategy for preventin...
Intravenous drug users are the second most common risk group for acquired immunodeficiency syndrome ...
AbstractEvidence-based strategies to guide human immunodeficiency virus (HIV) prevention for people ...
Major research findings show gaps in health services research on the prevalence and outcomes of pati...
During 2016, 6% of persons in the United States who received a diagnosis of human immunodeficiency v...
Human Immunodeficiency Virus-1 infection is prevalent among injection drug users nationwide, and is ...
Drug abuse is associated with poorer virologic and clinical outcomes for patients with human immunod...
During 2016, 6% of persons in the United States who received a diagnosis of human immunodeficiency v...
Background: Despite the development of antiretroviral therapy (ART), injection drug users (IDU) cont...
IntroductionPersons who inject drugs (PWID) continue to be disproportionately affected by HIV. HIV t...
During the last three decades, both the injection of illicit psychoactive drugs and HIV infection am...
Heterosexual contact with intravenous drug users accounts for a growing proportion of cases of acqui...